Xencor reported $-33975000 in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Abbvie ABBV:US $ 924M 3566M
Alnylam Pharmaceuticals ALNY:US $ -277.4M 37.06M
Amgen AMGN:US $ 1317M 159M
Arrowhead Research ARWR:US $ -72046000 116.41M
AstraZeneca AZN:LN 360M 26M
Biogen BIIB:US $ 1058M 754.2M
Bristol Myers Squibb BMY:US $ 1421M 143M
Cytokinetics CYTK:US $ -19.82M 69.62M
Epizyme EPZM:US $ -35.74M 19.76M
GlaxoSmithKline GSK:LN 838M 964M
Johnson & Johnson JNJ:US $ 4814M 335M
Karyopharm Therapeutics KPTI:US $ -49062000 7.66M
Macrogenics MGNX:US $ -41.3M 25.14M
Merk MRK:US $ 3944M 366M
Novartis NOVN:VX SF 1694M 528M
Pfizer PFE:US $ 9905M 2042M
Regeneron Pharmaceuticals REGN:US $ 852.1M 121.4M
Seattle Genetics SGEN:US $ -134.83M 1.67M
Xencor XNCR:US $ -33.98M 57.57M